A groundbreaking study has revealed a significant link between the frequency of chest x-ray referrals from GPs and earlier diagnosis and improved survival rates for lung cancer patients.

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

A consortium of Austrian research groups from the University of Vienna, MedUni Vienna and Technikum Wien, together with ...

When diagnosing lung metastases and second primary lung cancer in patients with head and neck cancer, low-dose CT leads to ...

Small-cell lung cancer is a highly malignant form of lung cancer, also known as oat-cell carcinoma, that accounts for approximately 15% of lung cancer cases. Composed of small, ovoid cells with ...

Doctors stage non-small cell lung cancer (NSCLC) according to how far it has progressed. Stages range from occult (or hidden) cancer to stage 4 cancer, in which multiple organs may be affected.

HUNTSVILLE, Ala. (WAFF) - The VA Clinic in Huntsville showed off new technology on Friday that is run by robots and helps detect lung cancer. It’s a less-invasive method than using cameras. Birmingham ...

Non-small cell lung cancer (NSCLC) constitutes a significant proportion of lung cancer cases, and despite advancements in treatment modalities, radiotherapy resistance remains a substantial hurdle in ...

2Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York. Search for other works by this author on: ...

Metastatic lung cancer can spread to any structure or organ in the body, including the brain, liver, lymph nodes, and adrenal glands. It is also known as stage 4 non-small cell lung cancer (NSCLC).

The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...